Management of Cesarean Section Uterine Scar Ectopic Pregnancy Type 2 Using Methotrexate: Insights from a Case Report

Taylor Pigg; Susan Fields; Amalia Brawley; R. Paul Roddenberry; Padmashree C. Woodham

doi:10.12659/AJCR.948357

24 September 2025 : Case report USA

Management of Cesarean Section Uterine Scar Ectopic Pregnancy Type 2 Using Methotrexate: Insights from a Case Report

Unusual or unexpected effect of treatment

Taylor Pigg^{BCDEF 1*}, Susan Fields^{BCDEF 1}, Amalia Brawley^{BCDEF 1,2,3}, R. Paul Roddenberry^{E 4}, Padmashree C. Woodham

^{BCDEF 1,2,3}

DOI: 10.12659/AJCR.948357

Am J Case Rep 2025; 26:e948357

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 beta-Human Chorionic Gonadotropin (β-HCG) vs time. Data points include serum quantitative β-hCG values (uMI/mL) collected before and after injection of intra-gestational methotrexate.

Specimen collection date	Quantitative β-HCG
Pre-procedure (5 weeks, 5 days)	18 194
Pre-procedure (6 weeks, 3 days)	40 035.21
Procedure Day	------------
Post-op Day 2	34 759.04
Post-op Day 4	49 887
Post-op Day 7	42 888
Post-op Day 13	7619
Post-op Day 20	2814
Post-op Day 27	997.1
Post-op Day 34	493
Post-op Day 43	220
Post-op Day 49	147.7
Post-op Day 59	91
Post-op Day 71	105
Post-op Day 73	108
Post-op Day 76	95
Post-op Day 101	69
Post-op Day 135	18
Post-op Day 161	3

Back to the Article

Management of Cesarean Section Uterine Scar Ectopic Pregnancy Type 2 Using Methotrexate: Insights from a Case Report

Your Privacy